PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.

Stenehjem, David D; Tran, Dao; Nkrumah, Michael A; Gupta, Shilpa

Stenehjem, David D; Tran, Dao; Nkrumah, Michael A; Gupta, Shilpa.

Afiliação

Stenehjem DD; Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota.
Tran D; Masonic Cancer Center, University of Minnesota, guptash@umn.edu.
Nkrumah MA; Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota.
Gupta S; Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota.

Onco Targets Ther ; 11: 5973-5989, 2018.

Article em En | MEDLINE | ID: mdl-30275703

Palavras-chave

bladder cancer; checkpoint inhibitors; immunotherapy; pembrolizumab; tumor-mutation burden; urothelial cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Onco Targets Ther Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google